Dried Blood Spot (DBS) PCR in Neonatal HIV Diagnosis

Dried Blood Spot (DBS) Polymerase Chain Reaction (PCR) is the cornerstone of Early Infant Diagnosis (EID) programs for HIV, particularly in resource-limited settings. It allows for the detection of the virus itself rather than antibodies, which is crucial in infants.

Rationale and Indication

• Maternal Antibodies: Infants born to HIV-infected mothers passively acquire maternal IgG antibodies across the placenta. These antibodies persist in the infant's blood for up to 18 months. Therefore, standard antibody tests (ELISA/Rapid tests) are not diagnostic for infection in children <18 months.
• Virological Testing: Diagnosis in this age group requires the detection of the virus (virological testing). PCR is the preferred method.
• DBS Utility: DBS involves collecting capillary blood on filter paper. It is preferred in programmatic settings because:
  • It stabilizes the nucleic acid (DNA/RNA).
  • It does not require a cold chain for transport (can be mailed).
  • It requires a smaller volume of blood than venous sampling.

Procedure and Target

• Collection: Blood is typically obtained via a heel prick and spotted onto specific filter paper cards.
• Target: The test detects HIV-1 Proviral DNA (integrated virus) or Total Nucleic Acid (TNA) (both RNA and DNA). The Indian National Program (Early Infant Diagnosis) utilizes HIV Total Nucleic Acid PCR on DBS.
• Sensitivity/Specificity: HIV DNA PCR is highly sensitive and specific. Sensitivity increases rapidly from birth to 95% at 4 weeks and 99% by 6 months of age.

Testing Schedule (NACO/WHO Guidelines)

• Routine Testing: The standard recommendation is to perform the first DBS PCR at 6 weeks of age (often coinciding with the first immunization visit).
• High-Risk Infants: For infants at high risk of transmission (e.g., mother with high viral load, no ART, or symptomatic infant), additional testing (Nucleic Acid Testing or NAT) may be considered at birth (within 48 hours) to detect intrauterine infection.
• Breastfed Infants: Since breastfeeding poses an ongoing risk of transmission, a negative result at 6 weeks does not rule out future infection. Repeat testing is required (e.g., at 6 months, 12 months, and 6 weeks after cessation of breastfeeding).

Diagnostic Algorithm

• Screening: Perform HIV-1 DNA PCR (or TNA PCR) on DBS at 6 weeks.
• Positive Result: A positive DBS result is considered presumptive. It must be confirmed by a second virological test using a separate whole blood sample (not DBS) repeated at the earliest opportunity to rule out operational errors.
• Negative Result:
  • If the infant is asymptomatic and not breastfeeding: Presumptively uninfected (definitive exclusion requires two negative tests or negative antibody after 18 months).
  • If the infant is breastfeeding: Continue prophylactic Cotrimoxazole and re-test according to the schedule (6 months, 9 months, or upon becoming symptomatic).

Use in Other Conditions

• Cytomegalovirus (CMV): DBS has been evaluated for congenital CMV screening but is generally not recommended due to low sensitivity compared to saliva or urine PCR.
• Enterovirus: RT-PCR on dried blood spots can detect enterovirus infections in neonates with sepsis-like illness.
• SCID: Newborn screening for Severe Combined Immunodeficiency (SCID) uses DBS to measure T-cell receptor excision circles (TRECs) to identify T-cell lymphopenia.